220 related articles for article (PubMed ID: 24773608)
21. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
[TBL] [Abstract][Full Text] [Related]
22. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?
Perachino M; Cavalli V; Bravi F
BJU Int; 2010 Mar; 105(5):648-51. PubMed ID: 19747358
[TBL] [Abstract][Full Text] [Related]
23. Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892).
Collette L; de Reijke TM; Schröder FH;
Eur Urol; 2003 Aug; 44(2):182-9; discussion 189. PubMed ID: 12875936
[TBL] [Abstract][Full Text] [Related]
24. The prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer.
Kim KH; Han KS; Kim KH; Kim DK; Koo KC; Rha KH; Choi YD; Hong SJ
Urol Oncol; 2015 Sep; 33(9):383.e17-22. PubMed ID: 26004165
[TBL] [Abstract][Full Text] [Related]
25. Predictors for response to intermittent androgen deprivation (IAD) in prostate cancer cases with biochemical progression after surgery.
Sciarra A; Cattarino S; Gentilucci A; Alfarone A; Innocenzi M; Gentile V; Salciccia S
Urol Oncol; 2013 Jul; 31(5):607-14. PubMed ID: 21665494
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of time to prostate-specific antigen (PSA) nadir and its relationship to survival beyond time to PSA nadir for prostate cancer patients with bone metastases after primary androgen deprivation therapy.
Teoh JY; Tsu JH; Yuen SK; Chan SY; Chiu PK; Lee WM; Wong KW; Ho KL; Hou SS; Ng CF; Yiu MK
Ann Surg Oncol; 2015 Apr; 22(4):1385-91. PubMed ID: 25234025
[TBL] [Abstract][Full Text] [Related]
27. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
Chung CS; Chen MH; Cullen J; McLeod D; Carroll P; D'Amico AV
Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
[TBL] [Abstract][Full Text] [Related]
28. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
29. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
[TBL] [Abstract][Full Text] [Related]
30. Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer.
Rodrigues NA; Chen MH; Catalona WJ; Roehl KA; Richie JP; D'Amico AV
Cancer; 2006 Aug; 107(3):514-20. PubMed ID: 16795068
[TBL] [Abstract][Full Text] [Related]
31. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
Duchesne GM; Woo HH; Bassett JK; Bowe SJ; D'Este C; Frydenberg M; King M; Ledwich L; Loblaw A; Malone S; Millar J; Milne R; Smith RG; Spry N; Stockler M; Syme RA; Tai KH; Turner S
Lancet Oncol; 2016 Jun; 17(6):727-737. PubMed ID: 27155740
[TBL] [Abstract][Full Text] [Related]
32. Treatment strategy for metastatic prostate cancer with extremely high PSA level: reconsidering the value of vintage therapy.
Yamada Y; Sakamoto S; Amiya Y; Sasaki M; Shima T; Komiya A; Suzuki N; Akakura K; Ichikawa T; Nakatsu H
Asian J Androl; 2018; 20(5):432-437. PubMed ID: 29735818
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer.
Kwak C; Jeong SJ; Park MS; Lee E; Lee SE
J Urol; 2002 Sep; 168(3):995-1000. PubMed ID: 12187207
[TBL] [Abstract][Full Text] [Related]
34. Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era.
Oefelein MG; Ricchiuti VS; Conrad PW; Goldman H; Bodner D; Resnick MI; Seftel A
Urology; 2002 Jul; 60(1):120-4. PubMed ID: 12100936
[TBL] [Abstract][Full Text] [Related]
35. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
Soga N; Arima K; Sugimura Y
Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
[TBL] [Abstract][Full Text] [Related]
36. Prostate-specific antigen kinetics under androgen deprivation therapy and prostate cancer prognosis.
Zhang LM; Jiang HW; Tong SJ; Zhu HQ; Liu J; Ding Q
Urol Int; 2013; 91(1):38-48. PubMed ID: 23774685
[TBL] [Abstract][Full Text] [Related]
37. Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer.
Langenhuijsen JF; Badhauser D; Schaaf B; Kiemeney LA; Witjes JA; Mulders PF
Urol Oncol; 2013 Jul; 31(5):549-56. PubMed ID: 21561791
[TBL] [Abstract][Full Text] [Related]
38. Survival outcomes of Chinese metastatic prostate cancer patients following primary androgen deprivation therapy in relation to prostate-specific antigen nadir level.
Teoh JY; Tsu JH; Yuen SK; Chan SY; Chiu PK; Wong KW; Ho KL; Hou SS; Ng CF; Yiu MK
Asia Pac J Clin Oncol; 2017 Apr; 13(2):e65-e71. PubMed ID: 25471685
[TBL] [Abstract][Full Text] [Related]
39. Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir.
Alexander AS; Mydin A; Jones SO; Christie J; Lim JT; Truong PT; Ludgate CM
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e713-9. PubMed ID: 21277102
[TBL] [Abstract][Full Text] [Related]
40. Elevated IL-8, TNF-α, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival.
Sharma J; Gray KP; Harshman LC; Evan C; Nakabayashi M; Fichorova R; Rider J; Mucci L; Kantoff PW; Sweeney CJ
Prostate; 2014 Jun; 74(8):820-8. PubMed ID: 24668612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]